Cocrystal Pharma Q1 2022 Earnings Report
Key Takeaways
Cocrystal Pharma reported a net loss of $4.2 million, or $0.04 per share, for the first quarter of 2022. The company's cash balance was $54.8 million as of March 31, 2022, which is expected to fund planned operations through 2023. The company is advancing its antiviral programs for influenza and COVID-19, with Phase 1 studies underway or planned.
Reported progress with antiviral programs for influenza and COVID-19.
Announced favorable preliminary safety and pharmacokinetic data from the first two cohorts of healthy adults in the Phase 1 study of CC-42344 for influenza A.
Advancing toward the start of a Phase 1 study with CDI-45205 for the treatment of COVID-19.
Cash balance of $54.8 million is expected to fund planned operations through 2023.
Cocrystal Pharma
Cocrystal Pharma
Forward Guidance
The Company expects R&D expenses to increase during 2022 due to the advancement of its influenza A program into the clinic and progress with preclinical COVID-19 programs toward clinical development.